5-(2-环氧乙烷基)-8-(苯基甲氧基)-2(1H)-喹啉酮 | 112281-28-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 5-(2-环氧乙烷基)-8-(苯基甲氧基)-2(1H)-喹啉酮
• 英文名称: 8-(benzyloxy)-5-(2-oxiranyl)quinolin-2(1H)-one
• 英文别名: 5-(2-Oxiranyl)-8-(phenylmethoxy)-2(1H)-quinolinone；5-(oxiran-2-yl)-8-phenylmethoxy-1H-quinolin-2-one
• CAS: 112281-28-4
• 化学式: C₁₈H₁₅NO₃
• 分子量: 293.322
• InChiKey: IHJYYLJZVBVLEK-UHFFFAOYSA-N

物化性质

• 熔点：
  114-116 °C
• 沸点：
  556.0±50.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(2-环氧乙烷基)-8-(苯基甲氧基)-2(1H)-喹啉酮 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 正丁醇 为溶剂， 反应 29.0h， 生成 5-<2-<<1-(4-iodophenyl)-2-methylprop-2-yl>amino>-1-hydroxyethyl>-8-hydroxycarbostyril
  参考文献：
  名称：

  Carbostyril derivatives having potent .beta.-adrenergic agonist properties

  摘要：

  Derivatives carrying a substituent in the para position of the phenyl group of 8-hydroxy-5-[2-[(1-phenyl-2-methylprop-2-yl)amino]-1-hydroxyethyl] carbostyril (10) were prepared and their effects on beta-adrenoceptors evaluated in vitro. Unsubstituted compound 10, iodo 11, amino 12, and bromoacetamido 13 derivatives (all racemic) bound to the receptor with 15-100-fold lower dissociation constants than that of (-)-isoproterenol. All the above compounds stimulated adenylate cyclase more potently than (-)-isoproterenol. The intrinsic activities of compounds 10 and 12 were equal to that of (-)-isoproterenol. The intrinsic activities of compounds 11 and 13 were 1.3 and 1.2 times that of (-)-isoproterenol, respectively. Treatment of membrane preparations with bromoacetamido derivative 13 resulted in an irreversible loss of binding sites, and thus, 13 seems to be an alkylating affinity label for beta-adrenoceptors.

  DOI：

  10.1021/jm00392a006
• 作为产物：
  描述：

  (8-苯基甲氧基喹啉-5-基)甲醇 在 乙酸酐 、 sodium hydride 、 二甲基亚砜 、 间氯过氧苯甲酸 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 生成 5-(2-环氧乙烷基)-8-(苯基甲氧基)-2(1H)-喹啉酮
  参考文献：
  名称：

  Carbostyril derivatives having potent .beta.-adrenergic agonist properties

  摘要：

  Derivatives carrying a substituent in the para position of the phenyl group of 8-hydroxy-5-[2-[(1-phenyl-2-methylprop-2-yl)amino]-1-hydroxyethyl] carbostyril (10) were prepared and their effects on beta-adrenoceptors evaluated in vitro. Unsubstituted compound 10, iodo 11, amino 12, and bromoacetamido 13 derivatives (all racemic) bound to the receptor with 15-100-fold lower dissociation constants than that of (-)-isoproterenol. All the above compounds stimulated adenylate cyclase more potently than (-)-isoproterenol. The intrinsic activities of compounds 10 and 12 were equal to that of (-)-isoproterenol. The intrinsic activities of compounds 11 and 13 were 1.3 and 1.2 times that of (-)-isoproterenol, respectively. Treatment of membrane preparations with bromoacetamido derivative 13 resulted in an irreversible loss of binding sites, and thus, 13 seems to be an alkylating affinity label for beta-adrenoceptors.

  DOI：

  10.1021/jm00392a006

文献信息

• [DE] NEUE LANG WIRKSAME BETA-2-AGONISTEN, UND DEREN VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS<br/>[FR] NOUVEAUX BETA-2 AGONISTES A EFFET PROLONGE ET LEUR UTILISATION COMME MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005070908A1

  公开（公告）日：2005-08-04

  Die vorliegende Erfindung betrifft Verbindungen der Formel (1), worin die Gruppen X, Ra, Rb, R1, R1', R2, R2', R2'', R2''', V und n die in den Ansprüchen und in der Beschreibung genannten Bedeutungen haben können, sowie deren Verwendung als Arzneimittel, insbesondere zur Behandlung von entzündlichen und obstruktiven Atemwegserkrankungen.

  本发明涉及式(1)的化合物，其中X、Ra、Rb、R1、R1'、R2、R2'、R2''、R2'''、V和n可以是权利要求和说明书中所指的含义，以及它们用作药物，尤其是用于治疗炎性和阻塞性呼吸道疾病。
• [DE] HYDROXY-SUBSTITUIERTE BENZKONDENSIERTE HETEROZYKLEN ALS BETAAGONISTEN ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN<br/>[EN] HYDROXY-SUBSTITUTED BENZO-CONDENSED HETEROCYCLES FOR USE AS BETA AGONISTS IN THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] HETEROCYCLES BENZOCONDENSES SUBSTITUES PAR HYDROXY UTILISES COMME BETA-AGONISTES POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005110990A1

  公开（公告）日：2005-11-24

  Die vorliegende Erfindung betrifft Verbindungen der allgemeinen Formel (1) worin die Reste n, A, B, R1, R2 und R3 die in den Ansprüchen und in der Beschreibung genannten Bedeutungen haben können, Verfahren zu deren Herstellung, sowie deren Verwendung als Arzneimittel, insbesondere als Arzneimittel zur Behandlung von Atemwegserkrankungen.

  本发明涉及具有通用公式(1)的化合物，其中n、A、B、R1、R2和R3的含义可以如要求和说明中所述，其制造方法，以及其作为药物的使用，尤其是作为治疗呼吸道疾病的药物的使用。
• Beta agonists for the treatment of respiratory diseases
  申请人：Konetzki Ingo

  公开号：US20050277632A1

  公开（公告）日：2005-12-15

  The present invention relates to compounds of general formula 1 wherein the groups n, A, B, R 1 , R 2 and R 3 may have the meanings given in the claims and in the specification, processes for preparing them, and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

  本发明涉及具有通用公式1的化合物，其中n、A、B、R1、R2和R3的含义如权利要求和说明书中所给，以及它们的制备过程和作为药物组合物的用途，尤其是作为治疗呼吸系统疾病的药物组合物的用途。
• New long acting beta-2-agonists and their use as medicaments
  申请人：Bouyssou Thierry

  公开号：US20050227975A1

  公开（公告）日：2005-10-13

  The present invention relates to compounds of formula 1 wherein the groups X, R a , R b , R 1 , R 1′ , R 2 , R 2′ , R 2″ , R 2′″ , V and n may have the meanings given in the claims and in the specification, and the use thereof as pharmaceutical compositions, particularly for the treatment of inflammatory and obstructive respiratory complaints.

  本发明涉及公式1的化合物，其中X、Ra、Rb、R1、R1′、R2、R2′、R2″、R2′″、V和n的含义如权利要求和说明书中所述，以及它们作为药物组合物的用途，特别是用于治疗炎性和阻塞性呼吸道疾病。
• Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
  申请人：KONETZKI Ingo

  公开号：US20070037781A1

  公开（公告）日：2007-02-15

  Disclosed are medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups X, R a , R b , R 1 , R 1′ , R 2 , R 2′ , R 2″ , R 2′″ , V and n may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

  公开了药物组合物，除了一个或多个，最好是1个，通用公式1中的化合物之外，还包括至少一个其他活性物质2，其中X，Ra，Rb，R1，R1′，R2，R2′，R2″，R2′″，V和n的含义如权利要求和说明书中所述，以及它们的制备方法和作为药物组合物用途。